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Electroporation is a physical method in which high voltage direct
current electric pulses cause non-selective plasma membrane
permeabilization. This method is widely used for introduction of
molecules such as DNA, antibodies, enzymes, dyes and drugs into
cells (Orlowski and Mir, 1993). The use of electric pulses to facil-
itate delivery of chemotherapeutic drugs into tumour cells was
termed electrochemotherapy and was introduced by Okino (Okino
and Mohri, 1987) and Mir (Mir et al, 1991). Anti-tumour effec-
tiveness of electrochemotherapy with the chemotherapeutic drugs
bleomycin and cisplatin has been extensively elaborated on
various tumour models in vivo (Sers ˘a et al, 1994, 1995; Heller et
al, 1995; Mir et al, 1995), and was also demonstrated to be
effective in treatment of accessible tumour nodules of various
malignancies in cancer patients (Mir et al, 1998; Sers ˘a et al,
1998a).
The critical intracellular target for cytotoxicity of both cisplatin
and bleomycin is DNA. Bleomycin causes single- and double-
stranded breaks in DNA, whereas cytotoxicity of cisplatin is
believed to be due to the formation of DNA adducts (Chu, 1994;
Mir et al, 1996). Therefore, the cytotoxicity of drugs is dependent
on their intracellular concentration and also upon membrane
permeability (Chu, 1994; Mir et al, 1996). It was shown that
electroporation of cells in vitro potentiates cytotoxicity of
bleomycin by several hundred times (Poddevin et al, 1991) and
cytotoxicity of cisplatin up to 70 times (Sers ˘a et al, 1995).
Electroporation of tumour cells in vivo has been demonstrated to
potentiate anti-tumour effectiveness of bleomycin and cisplatin
several-fold (Mir et al, 1991; Heller et al, 1995; Sers ˘a et al, 1995).
A high degree of tumour complete responses, as well as tumour
cures, were observed at low drug concentrations without systemic
toxicity. Studies demonstrating that electroporation increases
accumulation of radiolabelled [57Co]bleomycin in the cells in vitro
(Poddevin et al, 1991) and tumours in vivo (Belehradek et al,
1994) have already been performed.
Whether anti-tumour effectiveness of electrochemotherapy in
vivo is due to the increased cisplatin delivery into the tumour cells,
caused by electroporation, has been speculated (Sers ˘a et al, 1995)
but not shown. To answer this question, anti-tumour effectiveness
of electrochemotherapy on SA-1 tumours in mice, platinum
accumulation in the tumours, and the amount of platinum bound 
to DNA were measured.
MATERIALS AND METHODS
Animals and tumour model
In the experiments, the inbred strain of A/J mice were used, which
were purchased from Rudjer Bos ˘kovic ˘ Institute (Zagreb, Croatia).
They were kept at constant room temperature (24°C) with a
natural day/night light cycle in a conventional animal colony.
Before the experiments, the mice were subjected to an adaptation
period of at least 10 days. Female mice in good condition, without
fungal or other infections, weighing 20–22 g and 10–12 weeks of
age were included in experiments.
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The fibrosarcoma SA-1 tumour model (The Jackson
Laboratory, Bar Harbor, ME, USA), syngeneic to A/J mice, was
used in the study. Tumour cells were obtained from the ascitic
form of the tumours in mice, serially transplanted every 7 days.
Solid subcutaneous tumours, located dorsolaterally in mice, were
initiated by an injection of 5 ´ 105 SA-1 cells in 0.1 ml 0.9%
sodium chloride solution. The viability of the cells was over 95%
as determined by the Trypan blue dye exclusion test. Six days after
transplantation, when the tumours reached approximately 40 mm3
in volume, mice were randomly divided into experimental groups,
and subjected to a specific experimental protocol.
Electrochemotherapy protocol
cis-Diamminedichloroplatinum (II) (cisplatin) was obtained from
Bristol Myers Squibb (Austria) as a crystalline powder and
dissolved in sterile water at a concentration of 1 mg ml–1. The final
cisplatin solution was freshly prepared in 0.9% sodium chloride
each day. Cisplatin at a dose of 4 mg kg–1 was injected intra-
venously into the retro-orbital sinus. Injection volume was
0.0075 ml g–1 body weight.
Eight square-wave electric pulses of 1040 V amplitude, with a
pulse width of 100 ms and repetition frequency 1 Hz were deliv-
ered by two flat, parallel stainless-steel electrodes 8 mm apart (two
stainless-steel strips: length 35 mm, width 7 mm with rounded
corners), which were placed percutaneously at the opposite
margins of the tumour. Good contact between the electrodes and
the skin was assured by means of conductive gel. Electric pulses
were generated by an electropulsator Jouan GHT 1287 (Saint
Herblaine, France). In the electrochemotherapy protocol, mice
were treated with electric pulses 3 min after cisplatin injection. All
treatments were performed without anaesthesia and were well
tolerated by the animals.
Tumour growth was followed by measuring three mutually
orthogonal tumour diameters (e1, e2 and e3) with a vernier caliper
on each consecutive day. Tumour volumes were calculated by the
formula V = P´e1 ´ e2 ´ e3/6. From these measurements, the
arithmetic mean and standard error of the mean were calculated
for each experimental group. Tumour growth delay was calculated
for each individual tumour by subtracting the doubling time of
each tumour from the mean doubling time of the control group and
then averaged for each experimental group. Cell kill was calcu-
lated from the tumour growth curves using the formula: log10 cell
kill = tumour growth delay/3.32 ´ Td, in which 3.32 is the number
of cell doublings per log of growth and Td is tumour doubling time
(Corbett and Valeriote, 1987).
Platinum determination in the tumours and DNA
To determine platinum content in the tumours and the amount of
platinum bound to DNA, mice were sacrificed at various times
after treatment with intravenously injected cisplatin and after elec-
trochemotherapy. Tumours (six per group) were excised and
removed from the overlying skin.
For platinum determination in whole tumour, each tumour was
weighed (tumour weights were approximately 100 mg), placed
into a 15-ml graduated polyethylene tube and digested in 1 ml of
65% nitric acid by incubation at 37°C for at least 2 days to obtain
a clear solution. Samples were diluted with water to 10 ml before
analysis.
For determination of the amount of platinum bound to DNA,
each tumour was weighed, minced and treated with collagenase to
obtain a single cell suspension. DNA was isolated using a modi-
fied salting out method (Miller et al, 1988). Platinum content in
the samples was determined by electrothermal atomic absorption
spectrometry on a Hitachi Z-8270 Polarized Zeeman Atomic
Absorption Spectrophotometer, adjusted to a wavelength of 
265.9 nm (Milac ˘ic ˘ et al, 1997).
Histology of tumours
The tumours from control, electric pulse, cisplatin- and electro-
chemotherapy-treated animals were excised 3 days after the treat-
ment. Specimens were fixed immediately in 10% buffered neutral
formalin. One tissue block cut through the largest diameter of the
tumour was embedded in paraffin, and stained with haema-
toxylin–eosin by standard method. Slides of six tumours per group
were examined in a blind fashion. Tumour necrosis was deter-
mined in whole mount tumour section through the largest tumour
diameter.
Statistical analysis
The significance of differences between the mean values of
tumour growth delays, degree of necrosis and platinum concentra-
tion of the experimental groups was evaluated by a modified t-test
(Newman Keuls test), after a one-way analysis of variance was
performed and fulfilled.
RESULTS
Anti-tumour effectiveness
Treatment of animals with cisplatin as a single treatment (4 mg kg–1)
was ineffective and did not result in significant anti-tumour
Table 1 Anti-tumour effectiveness of electrochemotherapy on SA-1 tumours in mice
Therapy n Tumour doubling time Tumour growth delay
(days) AM±s.e.a (days) AM±s.e.a
Control 10 1.8 ± 0.1 –
Cisplatin 10 2.0 ± 0.1 0.2 ± 0.1
Electric pulses 10 3.7 ± 0.4 1.9 ± 0.4
Electrochemotherapy 10 12.1 ± 1.6 10.3 ± 1.6
aArithmetic mean ± standard error of the mean.1388 M C ˘emaz ˘ar et al
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effectiveness compared with the control group (P > 0.05) (Table 1,
Figure 1). The treatment was well tolerated by the animals, body
weight was not changed and no mortality was observed (data not
shown).
Electric pulses as a single treatment were moderately effective
(Table 1, Figure 1). Tumour growth delay was significantly
prolonged compared with the control, untreated group (P < 0.001).
The application of electric pulses had no side-effects and no
mortality of the animals was observed (data not shown).
Electrochemotherapy, combining intravenously injecting
cisplatin (4 mg kg–1) with an application of eight electric pulses to
the tumour (1040 V, 100 ms, 1 Hz) 3 min after the injection, was
very effective (Table 1, Figure 1). The reduction of tumour volume
was already detectable 3 days after the treatment. Thereafter, the
tumours gradually decreased in size for up to 7 days, when they
reached the pretreatment volume. Tumours were not exulcerated
nor had superficial scab. Regrowth of the tumours was observed
from the 8th day after the treatment. Their growth rate was approx-
imately the same as in the control groups, but their growth was
significantly delayed (P < 0.001) compared with control tumours
or those treated with cisplatin and electric pulses as single treat-
ment. Treatment with electrochemotherapy resulted in a log cell
kill of 0.62 and was more than 20-fold higher than cell kill of
cisplatin treatment alone (log cell kill = 0.03), as calculated from
tumour growth curves. Electrochemotherapy treatment was well
tolerated by the mice, body weight was not changed and no
mortality was observed (data not shown).
Tumour platinum accumulation and amount of platinum
bound to DNA
To determine whether the observed anti-tumour effectiveness of
electrochemotherapy can be associated with increased cisplatin
accumulation in the tumour cells, measurements of platinum
content in the tumours and the amount of platinum bound to DNA
were performed at different times after electrochemotherapy and
cisplatin treatment. Platinum content in the tumour and DNA
samples was determined by electrothermal atomic absorption
spectrometry (Figure 2, Figure 3). The initial level of platinum
in whole tumours was the same in both groups, and wash out of
platinum from the tumours was quick. However, significant
(P < 0.008) differences in the platinum content between the two
treatments was observed; after cisplatin treatment and electro-
chemotherapy, 50% of the initial level was obtained in 1 h and in
18 h respectively. At all time points except t = 0, the platinum
content in the tumours treated by electrochemotherapy was
approximately two times higher than in cisplatin-treated tumours
(Figure 2).
Already 3 min after the treatment, two times higher amounts of
platinum bound to DNA were detected in the tumours treated by
electrochemotherapy than in the tumours treated by cisplatin
alone. Thereafter, the amount of platinum bound to DNA in
electrochemotherapy-treated tumours increased, reaching the
maximum value 8 h after the treatment interval. This is in contrast
to cisplatin-treated tumours, in which the amount of platinum
bound to DNA was in the same range at all test times (Figure 3).
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Figure 1 The anti-tumour effectiveness of electrochemotherapy with
cisplatin on fibrosarcoma SA-1 subcutaneous tumours. Mice (ten per group)
were treated with cisplatin (4 mg kg–1) intravenously and/or with eight electric
pulses (1040 V, 100 ms, 1 Hz) 3 min after cisplatin injection. Tumour growth
curves represent the arithmetic mean ± standard error of the mean of the
tumour volumes measured every 2nd day
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Figure 2 Platinum concentration at different post-treatment intervals in
fibrosarcoma SA-1 tumours treated with cisplatin (4 mg kg–1) and
electrochemotherapy. Values represent arithmetic mean ± standard error of
the mean of six mice per measurement. *P < 0.05
20
0
4
8
12
16
0 4 8 12 16 20 24
Cisplatin
Electrochemotherapy
p
g
 
p
l
a
t
i
n
u
m
 
m
g
–
1
 
D
N
A
Time after treatment (h)
Figure 3 Amount of platinum bound to DNA of the cells obtained at
different post-treatment intervals from tumours treated with cisplatin (4 mg
kg–1) and electrochemotherapy. Values represent arithmetic mean ± standard
error of the mean of six mice per measurement. *P < 0.05Platinum accumulation in tumor cells after in vivo electrochemotherapy with cisplatin 1389
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Degree of necrosis
Necrosis of tumour tissue was evaluated in controls and in all
treatment groups 3 days after the beginning of treatment. The
degree of necrosis estimated histologically is shown in Figure 4.
Cisplatin treatment did not result in significantly increased
necrosis compared with controls. However, in tumours exposed
to electric pulses and in tumours treated with electrochemotherapy,
necrosis was increased significantly (P < 0.001). This degree of
necrosis was the highest in tumours treated with electro-
chemotherapy (38.2% ± 2.2%).
Histologically, necrosis in both control (Figure 5) and cisplatin-
treated (Figure 6) groups did not vary except for minor differences
in the degree. Focal geographic necroses of tumour cells were
characterized mostly by pyknosis, followed by coagulative type of
necrosis with preservation of the basic outlines of the tumour cells.
In the group treated with electric pulses, necrosis was advanced
with large areas of coagulative necrosis with loss of cellular struc-
tures (Figure 7). In tumours treated with electrochemotherapy,
however, irreversible cell injury was manifested also by confluent
areas of cells with distinct changes. Tumour cells were swollen
with enlarged vesicular nuclei and solitary or multiple clumped
nucleoplasmic condensations in granular background. Perinuclear
cytoplasm was condensed, eosinophilic and filled with multiple
blebs at the periphery of the cell (Figure 8).
DISCUSSION
Results of our study demonstrate that anti-tumour effectiveness of
electrochemotherapy with cisplatin is associated with increased
cisplatin accumulation in the tumours and increased amounts of
platinum bound to DNA due to electroporation in vivo. In
electrochemotherapy-treated tumours, more than twice the amount
of platinum was determined in whole tumours, as well as on 
DNA compared with cisplatin-treated ones. Because electro-
chemotherapy produced a more than 20-fold increase in cell kill
compared with cisplatin treatment alone, besides electroporation
other mechanisms could also be involved in anti-tumour effective-
ness of electrochemotherapy.
Electrochemotherapy with cisplatin has already been proven to
be effective in treatment of different tumours, as demonstrated in
preclinical (C ˘emaz ˘ar et al, 1995; Sers ˘a et al, 1995, 1997) as well
as in clinical studies (Sers ˘a et al, 1998a). However, it has not been
demonstrated yet that the marked increase in anti-tumour effec-
tiveness of cisplatin is due to the increased uptake of cisplatin by
the tumour cells after application of electric pulses.
Pharmacological studies of electrochemotherapy with belomycin,
which is another drug used in electrochemotherapy, have already
demonstrated that application of electric pulses to the tumours
markedly increases drug accumulation in the tumours (Belehradek
et al, 1994). Our study was, thus, undertaken to confirm that
cisplatin accumulation in the tumour cells after in vivo elec-
trochemotherapy is also increased.
Cisplatin is a chemotherapeutic drug whose transport through
the plasma membrane is restricted (Gately and Howell, 1993).
Bypassing the plasma membrane restriction by chemicals or elec-
tric pulses (Jekunen et al, 1993; Marverti et al, 1997; Melvik et al,
1986, Sers ˘a et al, 1995) could potentiate its anti-tumour effective-
ness. Jekunen et al (1993) demonstrated that uptake of
[3H]dichloro(ethylendiamine)platinum [II], an analogue of
cisplatin, could be increased into human ovarian carcinoma 2008
cells by treating the cells with the plasma membrane-selective
detergent digitonin. In addition, stimulation of cisplatin accumula-
tion was also achieved by treating 2008 cells and their resistant
subclone C13* with natural polycationic amine spermine
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Figure 4 Percentage of necrosis in the tumours 3 days after treatment with
cisplatin (4 mg kg–1), electric pulses and electrochemotherapy. Values
represent arithmetic mean ± standard error of the mean of six mice per
measurement. *P<0.05 Figure 5 Fibrosarcoma SA-1 in mouse. Control group. Focal geographic
necrosis with pyknotic nuclei (N) (objective 20´)
Figure 6 Fibrosarcoma SA-1 in mouse treated with cisplatin alone. Larger
areas of geographic necrosis (N) (objective 20´)1390 M C ˘emaz ˘ar et al
British Journal of Cancer (1999) 79(9/10), 1386–1391 © Cancer Research Campaign 1999
(Marverti et al, 1997). In our previous study, we demonstrated that
electroporation of B16 melanoma cells in vitro potentiated
cisplatin cytotoxicity up to 70 times (Sers ˘a et al, 1995). Results of
the present study demonstrate that tumour cell kill, platinum
content in the tumours and the amount of platinum bound to DNA
is increased in electrochemotherapy-treated tumours compared
with cisplatin treatment alone. It is well known that DNA platina-
tion is the major cytotoxic lesion induced by cisplatin and respon-
sible for cisplatin-induced cell death (Chu, 1994). Therefore, from
our results we can conclude that application of electric pulses to
tumours in vivo increases the permeability of the plasma
membrane of the cells and consequently enables cisplatin to enter
the cells and bind to DNA.
Other mechanisms that could contribute to the observed anti-
tumour effectiveness of electrochemotherapy could be involve-
ment of the immune system and modification of tumour blood
flow due to the application of electric pulses. The role of the
immune system in the anti-tumour effectiveness of electro-
chemotherapy with cisplatin has already been demonstrated (Sers ˘a
et al, 1997). In that study, we have compared anti-tumour effec-
tiveness of electrochemotherapy with cisplatin in immunocompe-
tent and immunodeficient mice. We found that tumour growth
delay in immunocompetent mice was approximately two times
longer than in immunodeficient mice, and furthermore a high
percentage of tumour cures was obtained in immunocompetent
mice in contrast to immunodeficient in which none of the animals
were cured. Thus, in the present study, the observed effectiveness
of electrochemotherapy could be ascribed also to contribution of
the immune system. After electrochemotherapy, less clonogenic
tumour cells remain than after cisplatin treatment, therefore the
immune system could be more effective in eradicating those cells.
Increased cell kill after electrochemotherapy as well as the
observed plateau in the platinum accumulation curve of up to 8 h
and the increase in the amount of platinum bound to DNA, with
the maximum value at 8 h after the treatment interval, may partly
be due to the vascular occlusion in the tumours exposed to electric
pulses. As observed in our previous study, besides electroporation,
electric pulses can modify tumour blood flow (Sers ˘a et al, 1998b).
Application of electric pulses such as those used in this study
reduce tumour blood flow by 60–70% and result in a tumour
growth delay of 0.2 days. The changes in blood flow are transient,
lasting for 1 h, thereafter tumour blood flow steadily recovers to
almost normal levels within 24 h. Having this in mind, the
observed retention of platinum in the tumours and increase in
DNA platination up to 8 h after the application of electric pulses
may be, in addition to electroporation, due to the blood-modifying
effect of electric pulses.
Morphological changes in the tumours correlate well with data
on anti-tumour effectiveness. Degree of tumour necrosis follows
the anti-tumour effectiveness of each therapeutic approach,
electrochemotherapy being the most successful. Specifically,
morphological changes of tumour cells in tumours treated with
electrochemotherapy were different and greater in extent than in
tumours treated with cisplatin only.
In conclusion, our study provides evidence that electroporation
of tumours in vivo increases uptake of cisplatin in cells. Electro-
chemotherapy with cisplatin has already been tested in a clinical
trial on malignant melanoma, squamous cell carcinoma and basal
cell carcinoma (Sers ˘a et al, 1998a). Therefore, this study further
supports this therapy by providing evidence of its underlying
mechanisms.
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